The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance
Abstract
MRI methods are widely used to follow the pathological evolution of multiple sclerosis in life and its modification by treatment. To date, measures of the number and volume of macroscopically visible lesions have been studied most often. These MRI outcomes have demonstrated clear treatment effects but without a commensurate clinical benefit, suggesting that there are other aspects of multiple sclerosis pathology that warrant investigation. In this context, there has been considerable interest in measuring tissue loss (atrophy) as a more global marker of the adverse outcome of multiple sclerosis pathology, whether it arises in macroscopic lesions or in the normal appearing tissues. An International Workshop recently considered the measurement of atrophy in multiple sclerosis and provided the basis for this review. Brain white matter bulk consists predominantly of axons (46%) followed by myelin (24%), and progressive atrophy implies loss of these structures, especially axons, although variable effects on tissue volumes may also arise from glial cell proliferation or loss, gliosis, inflammation and oedema. Significant correlations found between brain volume and other putative MR neuronal markers also indicate that atrophy reflects axonal loss. Numerous methods are available for the measurement of global and regional brain volumes and upper cervical cord cross-sectional area that are highly reproducible and sensitive to changes within 6-12 months. In general, 3D-T(1)-weighted acquisitions and largely automated segmentation approaches are optimal. Whereas normalized volumes are desirable for cross-sectional studies, absolute volume measures are adequate for serial investigation. Atrophy is seen at all clinical stages of multiple sclerosis, developing gradually following the appearance of inflammatory lesions. This probably reflects both inflammation-induced axonal loss followed by Wallerian degeneration and post-inflammatory neurodegeneration that may be partly due to failure of remyelination. One component of atrophy appears to be independent of focal lesions. Existing immunomodulatory therapies have had limited effects on progressive atrophy, concordant with their modest effects on progressive disability. Atrophy provides a sensitive measure of the neurodegenerative component of multiple sclerosis and should be measured in trials evaluating potential anti-inflammatory, remyelinating or neuroprotective therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voxel-Based Morphometry—The Methods
Ashburner, J., & Friston, K. J. (2000) · NeuroImage · doi:10.1006/nimg.2000.0582 · Cited by 8,676
Zhang, Y., Brady, M., & Smith, S. (2001) · IEEE Transactions on Medical Imaging · doi:10.1109/42.906424 · Cited by 6,982
A nonparametric method for automatic correction of intensity nonuniformity in MRI data
Sled, J. G., Zijdenbos, A. P., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.668698 · Cited by 4,731 · cited 1×
“Methods include ®tting a smoothly varying bias ®eld to the image data (Sled et al., 1998).”
MethodAxonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
Pfefferbaum, A., Mathalon, D. H., Sullivan, E. V., Rawles, J. M., Zipursky, R. B., & Lim, K. O. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540210046012 · Cited by 1,363
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
Courchesne, E., Chisum, H. J., Townsend, J., Cowles, A., Covington, J., Egaas, B., Harwood, M., Hinds, S., & Press, G. A. (2000) · Radiology · doi:10.1148/radiology.216.3.r00au37672 · Cited by 1,049
Adaptive fuzzy segmentation of magnetic resonance images
Pham, D. L., & Prince, J. L. (1999) · IEEE Transactions on Medical Imaging · doi:10.1109/42.802752 · Cited by 805
Cortical lesions in multiple sclerosis
Kidd, D., Barkhof, F., McConnell, R., Algra, P. R., Allen, I. V., & Revesz, T. (1999) · Brain · doi:10.1093/brain/122.1.17 · Cited by 766 · cited 1×
“Although there has been less pathological investigation of multiple sclerosis grey matter, plaques in grey matter are commonly recognized with careful post mortem examination (Kidd et al., 1999; Bù et al., 2000).”
BackgroundSelf-citation
Cited by
Ahuja, C. S., Wilson, J. R., Nori, S., Kotter, M. R. N., Druschel, C., Curt, A., & Fehlings, M. G. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.18 · Cited by 2,441
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
Hauser, S. L., & Oksenberg, J. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.011 · Cited by 776
Gray matter atrophy in multiple sclerosis: A longitudinal study
Fisher, E., Lee, J., Nakamura, K., & Rudick, R. A. (2008) · Annals of Neurology · doi:10.1002/ana.21436 · Cited by 670
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628
Gray matter atrophy is related to long‐term disability in multiple sclerosis
Fisniku, L. K., Chard, D. T., Jackson, J. S., Anderson, V. M., Altmann, D. R., Miszkiel, K. A., Thompson, A. J., & Miller, D. H. (2008) · Annals of Neurology · doi:10.1002/ana.21423 · Cited by 500
Self-citationAssociation between pathological and MRI findings in multiple sclerosis
Filippi, M., Rocca, M. A., Barkhof, F., Brück, W., Chen, J. T., Comi, G., DeLuca, G., De Stefano, N., Erickson, B. J., Evangelou, N., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70003-0 · Cited by 486
Self-citationHe, Y., Dagher, A., Chen, Z., Charil, A., Zijdenbos, A., Worsley, K., & Evans, A. (2009) · Brain · doi:10.1093/brain/awp089 · Cited by 452
on behalf of the MAGNIMS study group, Rovira, À., Wattjes, M. P., Tintoré, M., Tur, C., Yousry, T. A., Sormani, M. P., De Stefano, N., Filippi, M., Auger, C., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.106 · Cited by 423
Self-citationRetinal nerve fiber layer is associated with brain atrophy in multiple sclerosis
Gordon-Lipkin, E., Chodkowski, B., Reich, D. S., Smith, S. A., Pulicken, M., Balcer, L. J., Frohman, E. M., Cutter, G., & Calabresi, P. A. (2007) · Neurology · doi:10.1212/01.wnl.0000295995.46586.ae · Cited by 419
Pathogenesis of axonal and neuronal damage in multiple sclerosis
Dutta, R., & Trapp, B. D. (2007) · Neurology · doi:10.1212/01.wnl.0000275229.13012.32 · Cited by 412
Focal thinning of the cerebral cortex in multiple sclerosis
Sailer, M. (2003) · Brain · doi:10.1093/brain/awg175 · Cited by 398
Regional hippocampal atrophy in multiple sclerosis
Sicotte, N. L., Kern, K. C., Giesser, B. S., Arshanapalli, A., Schultz, A., Montag, M., Wang, H., & Bookheimer, S. Y. (2008) · Brain · doi:10.1093/brain/awn030 · Cited by 389
Dalton, C. M. (2004) · Brain · doi:10.1093/brain/awh126 · Cited by 377
Brain atrophy and lesion load predict long term disability in multiple sclerosis
Popescu, V., Agosta, F., Hulst, H. E., Sluimer, I. C., Knol, D. L., Sormani, M. P., Enzinger, C., Ropele, S., Alonso, J., Sastre-Garriga, J., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304094 · Cited by 331
Cortical lesion load associates with progression of disability in multiple sclerosis
Calabrese, M., Poretto, V., Favaretto, A., Alessio, S., Bernardi, V., Romualdi, C., Rinaldi, F., Perini, P., & Gallo, P. (2012) · Brain · doi:10.1093/brain/aws246 · Cited by 329
Neocortical volume decrease in relapsing–remitting MS patients with mild cognitive impairment
Amato, M. P., Bartolozzi, M. L., Zipoli, V., Portaccio, E., Mortilla, M., Guidi, L., Siracusa, G., Sorbi, S., Federico, A., & De Stefano, N. (2004) · Neurology · doi:10.1212/01.wnl.0000129544.79539.d5 · Cited by 318
Epidemiology and treatment of multiple sclerosis in elderly populations
Vaughn, C. B., Jakimovski, D., Kavak, K. S., Ramanathan, M., Benedict, R. H. B., Zivadinov, R., & Weinstock-Guttman, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0183-3 · Cited by 306
Measurement and clinical effect of grey matter pathology in multiple sclerosis
Geurts, J. J., Calabrese, M., Fisher, E., & Rudick, R. A. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70230-2 · Cited by 298
Mitochondrial Dysfunction and Multiple Sclerosis
Barcelos, I. P. D., Troxell, R. M., & Graves, J. S. (2019) · Biology · doi:10.3390/biology8020037 · Cited by 291
MR Imaging of Multiple Sclerosis
Filippi, M., & Rocca, M. A. (2011) · Radiology · doi:10.1148/radiol.11101362 · Cited by 281
on behalf of the MAGNIMS study group, Sastre-Garriga, J., Pareto, D., Battaglini, M., Rocca, M. A., Ciccarelli, O., Enzinger, C., Wuerfel, J., Sormani, M. P., Barkhof, F., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0314-x · Cited by 273
Biological markers in CSF and blood for axonal degeneration in multiple sclerosis
Teunissen, C. E., Dijkstra, C., & Polman, C. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00964-0 · Cited by 252
Perivascular spaces—MRI marker of inflammatory activity in the brain?
Wuerfel, J., Haertle, M., Waiczies, H., Tysiak, E., Bechmann, I., Wernecke, K. D., Zipp, F., & Paul, F. (2008) · Brain · doi:10.1093/brain/awn171 · Cited by 244
Xie, M., Tobin, J. E., Budde, M. D., Chen, C.-I., Trinkaus, K., Cross, A. H., McDaniel, D. P., Song, S.-K., & Armstrong, R. C. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181e3de90 · Cited by 175
Brain volume changes in CADASIL: A serial MRI study in pure subcortical ischemic vascular disease
Peters, N., Holtmannspötter, M., Opherk, C., Gschwendtner, A., Herzog, J., Sämann, P., & Dichgans, M. (2006) · Neurology · doi:10.1212/01.wnl.0000216271.96364.50 · Cited by 130
Versijpt, J., Debruyne, J. C., Van Laere, K. J., De Vos, F., Keppens, J., Strijckmans, K., Achten, E., Slegers, G., Dierckx, R. A., Korf, J., et al. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1140oa · Cited by 126
(2006) · PubMed Central · Cited by 126
Late motor decline after accomplished remyelination: Impact for progressive multiple sclerosis
Manrique‐Hoyos, N., Jürgens, T., Grønborg, M., Kreutzfeldt, M., Schedensack, M., Kuhlmann, T., Schrick, C., Brück, W., Urlaub, H., Simons, M., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22681 · Cited by 107
Uddin, M. N., Figley, T. D., Marrie, R. A., Figley, C. R., & for the CCOMS Study Group (2018) · NMR in Biomedicine · doi:10.1002/nbm.3868 · Cited by 84
Slowly eroding lesions in multiple sclerosis
Sethi, V., Nair, G., Absinta, M., Sati, P., Venkataraman, A., Ohayon, J., Wu, T., Yang, K., Shea, C., Dewey, B. E., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458516655403 · Cited by 34
De Masi, R., Vergara, D., Pasca, S., Acierno, R., Greco, M., Spagnolo, L., Blasi, E., Sanapo, F., Trianni, G., & Maffia, M. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.03.002 · Cited by 26
“Moreover, the brain atrophy has been proposed to monitor MS evolution and represents an additional exploratory measure of outcome in recent clinical trials (Miller et al., 2002).”
Background
Metadata
- Authors
- Miller, D. H.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-08-01
- Volume
- 125
- Issue
- 8
- Pages
- 1676-1695
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W1997024092
- Cited by
- 631
- References
- 81
- FWCI
- 24.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.